Proteomics

Dataset Information

0

The HLA-ligandome of oropharyngeal squamous cell carcinomas reveals shared tumor-exclusive peptides for semi-personalized vaccination


ABSTRACT: Oropharyngeal squamous cell carcinoma (OPSCC) is diagnosed in 93,000 patients worldwide per year and 51,000 annual deaths can be attributed to this disease. OPSCCs are either human papillomavirus associated (HPV-positive) cancers or non-virally induced, primarily tobacco and alcohol associated (HPV-negative) cancers. MS analysis enabled the identification of naturally HLA-presented peptides in OPSCC tumor tissue. By comparative profiling against benign HLA ligandomic datasets, we demonstrated that tumor-associated peptides are HLA-presented on the cell surfaces of OPSCCs. The established warehouse of OPSCC-associated peptides can be used for downstream immunogenicity testing and peptide-based immunotherapy in (semi-) personalized strategies.

INSTRUMENT(S): LTQ Orbitrap XL

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Tongue, Tonsil, Palate

DISEASE(S): Head And Neck Squamous Cell Carcinoma

SUBMITTER: Lena Mühlenbruch  

LAB HEAD: Simon Laban

PROVIDER: PXD033383 | Pride | 2023-02-27

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
OPSCC_01_ClassII_Rep-1.msf Msf
OPSCC_01_ClassII_Rep-1.raw Raw
OPSCC_01_ClassII_Rep-2.msf Msf
OPSCC_01_ClassII_Rep-2.raw Raw
OPSCC_01_ClassII_Rep-3.msf Msf
Items per page:
1 - 5 of 564
altmetric image

Publications


<h4>Background</h4>The immune peptidome of OPSCC has not previously been studied. Cancer-antigen specific vaccination may improve clinical outcome and efficacy of immune checkpoint inhibitors such as PD1/PD-L1 antibodies.<h4>Methods</h4>Mapping of the OPSCC HLA ligandome was performed by mass spectrometry (MS) based analysis of naturally presented HLA ligands isolated from tumour tissue samples (n = 40) using immunoaffinity purification. The cohort included 22 HPV-positive (primarily HPV-16) and  ...[more]

Similar Datasets

2018-12-11 | PXD010450 | Pride
2023-11-21 | PXD038782 | Pride
2022-07-19 | PXD035324 | Pride
2020-12-01 | PXD019258 | Pride
2019-10-14 | PXD015748 | Pride
2023-07-05 | PXD041804 | Pride
2017-11-02 | PXD007635 | Pride
2019-03-12 | PXD009602 | Pride
2015-07-14 | PXD001904 | Pride
2015-07-14 | PXD001872 | Pride